Epigral Limited Receives EcoVadis Silver Medal for Sustainability Excellence

1 min read     Updated on 03 Feb 2026, 05:07 PM
scanx
Reviewed by
Shriram SScanX News Team
Overview

Epigral Limited has been awarded the EcoVadis Silver Medal on February 3, 2026, placing the integrated chemical manufacturer in the top 15% of over 150,000 companies globally assessed for sustainability. The recognition spans four key areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement. Chairman Maulik Patel highlighted that this achievement reflects the company's deep integration of sustainability into business strategy and operations at its Dahej facility in Gujarat.

31664279

*this image is generated using AI for illustrative purposes only.

Epigral Limited, India's leading integrated chemical manufacturer, has achieved a significant milestone in sustainability by receiving the prestigious EcoVadis Silver Medal on February 3, 2026. This recognition places the company among the top performers globally in corporate sustainability and responsible business practices.

Global Recognition for Sustainability Excellence

The EcoVadis Silver Medal places Epigral in the top 15% of more than 150,000 companies worldwide that have been assessed by EcoVadis, recognized as the world's most trusted sustainability ratings provider. This achievement reflects the company's strong performance across four critical sustainability dimensions.

Assessment Areas: Performance Level
Environment: Strong Performance
Labor & Human Rights: Strong Performance
Ethics: Strong Performance
Sustainable Procurement: Strong Performance
Global Ranking: Top 15% of 150,000+ companies
Medal Type: Silver Medal

Leadership Commitment to Sustainable Growth

Chairman and Managing Director Maulik Patel expressed his satisfaction with this achievement, stating that the EcoVadis Silver rating affirms how deeply sustainability is woven into Epigral's business strategy and decision-making processes. He emphasized that this accolade highlights the team's shared dedication to responsible manufacturing, ethical standards, and relentless progress. Patel added that as the company expands, sustainability will remain at the core of efforts to deliver enduring value for all stakeholders.

Integrated Manufacturing Excellence

Epigral Limited, incorporated in 2007, operates from its state-of-the-art facility at Dahej, Gujarat. The company has established itself as a pioneer in India's chemical manufacturing sector, being the first to set up an Epichlorohydrin plant and operating the largest capacity plant of CPVC in the country.

Key Manufacturing Capabilities:

  • Caustic Soda - Leading manufacturer
  • Caustic Potash - Integrated production
  • Chloromethanes - Specialized chemicals
  • Hydrogen Peroxide - Industrial applications
  • Chlorine and Hydrogen - Essential chemicals
  • CPVC - Largest capacity in India
  • Epichlorohydrin - First plant in India

Strategic Focus on Specialty Chemicals

The company is strengthening its position in the specialty chemical business through capacity enhancement of CPVC and ECH, venturing into the Chlorotoluenes value chain, and establishing a dedicated R&D centre. This strategic approach aligns with Epigral's focus on sustainable value creation for all stakeholders while maintaining its commitment to environmental responsibility and ethical business practices.

The EcoVadis Silver Medal recognition reinforces Epigral's position as a responsible manufacturer committed to integrating ESG principles into its operations and value chain, demonstrating its long-term dedication to sustainable growth in India's chemical industry.

Historical Stock Returns for Epigral

1 Day5 Days1 Month6 Months1 Year5 Years
+12.05%-2.97%-17.00%-47.15%-43.39%+154.40%

Epigral Limited Publishes Q3 FY26 Results: Revenue Declines 7.5% YoY to ₹597.12 Crore

2 min read     Updated on 30 Jan 2026, 02:54 PM
scanx
Reviewed by
Radhika SScanX News Team
Overview

Epigral Limited reported challenging Q3 FY26 results with revenue declining 7.5% YoY to ₹597.12 crore and net profit falling 62.2% to ₹39.15 crore. The company has complied with SEBI regulations by publishing these unaudited financial results in Financial Express, with consolidated results showing minimal variance from standalone figures.

31310672

*this image is generated using AI for illustrative purposes only.

Epigral Limited, a leading chloro alkali manufacturer, announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company's Board of Directors approved the results at a meeting held on January 30, 2026, showing a challenging quarter with revenue and profitability pressures. The company has also fulfilled its regulatory obligations by publishing these results in Financial Express under Regulation 47 of SEBI listing requirements.

Financial Performance Overview

The company's operational performance reflected mixed trends across key metrics during the quarter:

Metric: Q3 FY26 Q3 FY25 Change (%)
Revenue from Operations: ₹597.12 crore ₹645.24 crore -7.5%
Total Income: ₹602.68 crore ₹649.10 crore -7.2%
Net Profit After Tax: ₹39.15 crore ₹103.54 crore -62.2%
Earnings Per Share: ₹9.08 ₹24.23 -62.5%

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, Epigral's performance showed year-over-year decline in key financial parameters:

Parameter: 9M FY26 9M FY25 Change (%)
Revenue from Operations: ₹1,791.02 crore ₹1,922.50 crore -6.8%
Net Profit After Tax: ₹251.08 crore ₹270.08 crore -7.0%
Earnings Per Share: ₹58.20 ₹64.38 -9.6%

Quarterly Performance Trends

The company's sequential performance showed improvement from the previous quarter:

Quarter Comparison: Q3 FY26 Q2 FY26 Sequential Change
Revenue from Operations: ₹597.12 crore ₹587.36 crore +1.7%
Net Profit After Tax: ₹39.15 crore ₹51.52 crore -24.0%
Earnings Per Share: ₹9.08 ₹11.87 -23.5%

Regulatory Compliance and Publication

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Epigral Limited published its unaudited financial results in Financial Express (English & Gujarati edition) on January 31, 2026. Company Secretary & Compliance Officer Gaurang Trivedi confirmed the newspaper publication to both NSE and BSE exchanges.

Consolidated vs Standalone Results

The consolidated financial results, which include associates ReNew Green (GJS Three) Private Limited and Pro-Zeal Green Power Ten Private Limited, showed minimal variance from standalone figures:

Results Type: Consolidated Net Profit Standalone Net Profit Variance
Q3 FY26: ₹39.11 crore ₹39.15 crore -₹0.04 crore
9M FY26: ₹251.02 crore ₹251.08 crore -₹0.06 crore

Business Operations and Market Position

Epigral operates primarily in the chloro alkali and its derivatives segment, with sales substantially in the domestic market. The company's business activities fall within a single reportable segment as per Indian Accounting Standards. The financial results demonstrate the company's continued focus on operational efficiency despite challenging market conditions in the chemical sector.

Historical Stock Returns for Epigral

1 Day5 Days1 Month6 Months1 Year5 Years
+12.05%-2.97%-17.00%-47.15%-43.39%+154.40%

More News on Epigral

1 Year Returns:-43.39%